Ats Corporation · TSX:ATS

Ats — ATS Automation Tooling Systems — Shareholder Meeting (August 2021)

28 slides from Ats's shareholder meeting presentation, Aug 12, 2021

  1. Slide 1: Annual and Special Meeting of Shareholders

    TSX: ATA 08.12.2021 ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

  2. Slide 2: David McAusland, Chairman of the Board

    DAVID McAUSLAND Chairman of the Board

  3. Slide 3: Presenters

    Presenters Andrew Hider CEO Ryan McLeod CFO 3

  4. Slide 4: Overcoming Covid-19 Challenges

    Overcoming Covid-19 Challenges 4

  5. Slide 5: Progress Report

    Progress Report 10 Year Adjusted EPS 10 Year Revenue EXPAND GROW 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 5 5

  6. Slide 6: Environmental, Social & Governance

    Environmental, Social & Governance EXPAND GROW 6 6

  7. Slide 7: Board of Director Nominees

    Board of Director Nominees Dave Cummings Kirsten Lange Philip Whitehead Joanne Ferstman Michael Martino Andrew Hider David McAusland 7

  8. Slide 8: Annual and Special Meeting of Shareholders

    TSX: ATA 08.12.2021 ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

  9. Slide 9: Agenda

    Agenda 1. Notice 2. Presentation of Financial Statements 3. Election of Directors 4. Re-appointment of Auditors 5. Confirmation of Advance Notice By-law 6. Business Termination 7. Management’s Remarks 8. Question Period 9

  10. Slide 10: Forward-Looking Statements

    Forward-Looking Statements Notice to Reader: This presentation and the oral statements made during this meeting contain certain statements that constitute forward-looking information within the meaning of applicable securities laws ("forward-looking statements"). Such forward-looking statements invo

  11. Slide 11: Andrew Hider, Chief Executive Officer

    ANDREW HIDER Chief Executive Officer

  12. Slide 12: ATS At-A-Glance

    ATS At-A-Glance ATA ~C$3.4bn TSX Mkt. Cap1 5,000+ C$1.4bn Employees Revenue (F21) 28 C$201mm Facilities Adj. EBITDA (F21) 50+ 14.0% Offices Adj. EBITDA Margin (F21) 22 1.7x Countries Net Leverage 9.1% 6.2% 15.8% v21 4-yr Rev. CAGR 4-yr Organic Rev. CAGR 4-yr Adj. EBITDA CAGR 12 ¹ As of August 4, 202

  13. Slide 13: Deliberate Portfolio Evolution

    Deliberate Portfolio Evolution F2021 8% 17% F2018 $1,430 56% 12% 19% F2016 14% 47% 7% $1,115 F2012 15% 42% 27% 13% 33% $1,039 13% $595 36% Life Sciences 41% Transportation Energy ATS Revenue Portfolio Evolution Consumer (C$ mm) 13

  14. Slide 14: Expanding Our Presence

    Expanding Our Presence Attractive Markets Barriers to Entry: Market Dynamics: ▪ Regulated environments ▪ Life Sciences: demographics, new treatments, Life Sciences Food ▪ Technologically intense new ailments, disposables ▪ Complex processes ▪ Food: government regs, quality, demographics ▪ Quality cr

  15. Slide 15: Large Total Addressable Markets

    Large Total Addressable Markets Strategically Positioned in Attractive Markets Levered to Positive Secular Trends F21 Sales LT Market Market Size¹ (C$ mm) Growth¹ Focus Areas Life Sciences ■ Medical Devices ■ Pharmaceuticals De-risking of Manufacturing $10bn $805mm MSD ■ Radiopharmaceuticals and Sup

  16. Slide 16: The ATS M&A Playbook

    The ATS M&A Playbook What We Look For Recent Acquisitions End Market Exposure ■ Growth orientated Targeting Value Creation in Attractive Markets Attractive ■ Low cyclicality Markets ■ Regulated spaces Acquired: Jun 2021 ✓ Life Sciences Price: US$84mm ■ Differentiated technology ■ Innovative products

  17. Slide 17: CFT Overview

    CFT Overview Business Overview Attractive Revenue Profile ▪ Established in 1945 and based in Parma, Italy Figures in Millions €254 Aftermarket Single ▪ Global supplier of processing and packaging equipment to €209 €226 20% Machines €189 30% the Food & Beverage industry €170 ▪ Leading brands in attra

  18. Slide 18: BioDot Overview

    BioDot Overview Business Overview Attractive Financial Profile ▪ Founded in 1994 and based in Irvine, California Figures in US$ Millions (1) ATS Outlook FY2022+ ▪ Manufacturer of mission-critical, ultra-low volume, $36.1 premium, non-contact and quantitative fluid dispensing Market Growth → HSD and

  19. Slide 19: The ATS Business Model

    The ATS Business Model STRENGTHEN OUR DELIVER GROWTH PURSUIT OF CORE EXCELLENCE Customer Customer Long Term First Success Value Performance Organization/Talent Strategic Planning Management Development Process Goal Deployment Value Drivers Monthly Business Reviews Continuous KPI’s Improvement Daily

  20. Slide 20: Summary

    Summary Attractive Markets ATS 40+ years TSX: ATA 27 years 20

  21. Slide 21: Ryan McLeod, Chief Financial Officer

    RYAN MCLEOD Chief Financial Officer

  22. Slide 22: Our Value Drivers

    Our 8 Value Drivers Financial: EBIT Working Bookings Revenue Capital Margin Customer: People: On-Time Internal Fill Employee Quality Delivery Rate Turnover Continuous Improvement 22

  23. Slide 23: Strong Performance Track Record

    Strong Performance Track Record Revenues (C$ mm) Order Bookings (C$ mm) $3,000 $2,000 +9.4% CAGR $2,500 $1,468 $1,626 $1,408 +9.1% CAGR $1,500 $2,000 $1,182 $1,134 $1,430 $1,430 $1,500 $1,115 $1,254 $1,000 $1,011 $1,000 $500 $500 $0 $0 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 Adj. EBITDA1 (

  24. Slide 24: Robust FCF & Ample Liquidity

    Robust FCF & Ample Liquidity Cumulative FCF Since 20171 (C$ mm) Working Capital as a % of Revenues $348 $350 20% $300 Target Range of <15% of Sales $230 15% $250 12.3% $200 $194 $144 10% 8.3% $150 8.0% 7.1% $110 6.0% $100 5% $50 $0 0% 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 Liquidity (C$ m

  25. Slide 25: Annual and Special Meeting of Shareholders

    TSX: ATA 08.12.2021 ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

  26. Slide 26: Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures

    Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures Notice to reader: Non-IFRS measures and additional IFRS measures Throughout this presentation management uses certain non-IFRS measures to evaluate the performance of the Company. The terms “adjusted EBITDA”, “adjusted EBITDA margin”, “n

  27. Slide 27: Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures

    Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures Measure (C$ mm) F2017 F2018 F2019 F2020 F2021 Measure (C$ mm) F2017 F2018 F2019 F2020 F2021 Adjusted EBITDA 111.7 133.3 161.9 195.1 200.7 Cash and cash 286.7 330.2 224.5 358.6 187.5 Restructuring charges 2.3 11.2 - 26.6 14.3 equivalents

  28. Slide 28: Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures

    Appendix: Reconciliation of Non-IFRS Measures to IFRS Measures Measure (C$ mm) F2017 F2018 F2019 F2020 F2021 Measure (C$ mm) F2017 F2018 F2019 F2020 F2021 Accounts receivable 166.1 213.0 222.2 294.8 294.1 Cash flows provided by 127.9 59.7 127.6 20.3 185.2 Net contract assets 48.2 69.0 52.4 113.8 54.

ATS Automation Tooling Systems — Shareholder Meeting (August 2021) on 6ix